EBS
Emergent BioSolutions Inc.
Price Chart
Latest Quote
$8.00
-0.14 (-1.72%)
Current Price
| Previous Close | $8.14 |
| Open | $8.22 |
| Day High | $8.32 |
| Day Low | $7.89 |
| Volume | 734,992 |
Stock Information
| Shares Outstanding | 51.60M |
| Total Debt | $584.60M |
| Cash Equivalents | $160.30M |
| Revenue | $676.80M |
| Net Income | $-8.60M |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Market Cap | $412.77M |
| EPS (TTM) | $-0.19 |
| Exchange | NYQ |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $837.07M |
| Sales | $676.80M |
| Income | $-8.60M |
| Book/sh | $10.10 |
| Cash/sh | $3.11 |
| Employees | 900 |
Financial Ratios
| Quick Ratio | 1.90 |
| Current Ratio | 4.29 |
| Debt/Eq | 111.76 |
| EPS Growth TTM | -90.00% |
Returns & Margins
| ROA | 3.43% |
| ROE | -1.60% |
| Gross Margin | 47.49% |
| Operating Margin | 6.79% |
| Profit Margin | -1.27% |
Ownership
| Insider Ownership | 3.85% |
| Institutional Ownership | 86.54% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | 2.68 |
| PEG | 0.38 |
| P/S | 0.61 |
| P/B | 0.79 |
Analyst Data
| Recommendation | none |
| Target Price | $12.00 |
Technical Indicators
| SMA20 | $8.37 |
| SMA50 | $8.40 |
| SMA200 | $9.71 |
| RSI | 35.26 |
| ATR | 0.4714 |
| Shares Float | 49.38M |
| Short Float | 19.22% |
| Short Ratio | 12.03 |
| Volatility | 2.33 |
| Rel Volume | 2.36 |
Performance History
| Week | -4.65% |
| Month | -0.74% |
| Quarter | -0.99% |
| 6 Months | -34.37% |
| YTD | -36.05% |
| Year | +28.62% |
| 3 Years | -1.11% |
| 5 Years | -87.40% |
| 10 Years | -79.65% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $8.00 | 2,229,000 |
| 2026-06-17 | $8.14 | 990,500 |
| 2026-06-16 | $7.75 | 1,824,400 |
| 2026-06-15 | $8.29 | 688,700 |
| 2026-06-12 | $8.32 | 476,700 |
| 2026-06-11 | $8.39 | 678,000 |
| 2026-06-10 | $8.24 | 780,400 |
| 2026-06-09 | $7.95 | 818,300 |
| 2026-06-08 | $8.00 | 605,400 |
| 2026-06-05 | $8.07 | 701,600 |
| 2026-06-04 | $8.44 | 935,600 |
| 2026-06-03 | $7.93 | 1,042,100 |
| 2026-06-02 | $8.21 | 802,400 |
| 2026-06-01 | $8.49 | 852,300 |
| 2026-05-29 | $9.12 | 1,157,300 |
| 2026-05-28 | $9.18 | 880,100 |
| 2026-05-27 | $9.00 | 821,100 |
| 2026-05-26 | $9.13 | 1,082,800 |
| 2026-05-22 | $8.45 | 986,700 |
| 2026-05-21 | $8.37 | 554,300 |
| 2026-05-20 | $8.15 | 614,600 |
| 2026-05-19 | $8.06 | 671,900 |
About Emergent BioSolutions Inc.
Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States, Canada, and internationally. It operates through Commercial Products, MCM Products, and All Other Revenues segments. The company offers ACAM2000, a smallpox and mpox vaccine; Anthrax Immune Globulin Intravenous (ANTHRASIL), a polyclonal antibody therapeutic for the treatment of inhalational anthrax; Botulism Antitoxin Heptavalent (BAT), an equine plasma antitoxin for the treatment of symptomatic botulism; BioThrax, an anthrax vaccine; CYFENDUS, a vaccine for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; Ebanga, a monoclonal antibody for the treatment of infection caused by Orthoebolavirus zairense; Raxibacumab injection, a monoclonal antibody therapeutic for the treatment and prophylaxis of inhalational anthrax due to Bacillus anthracis; TEMBEXA, an oral antiviral for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; and CNJ-016, a polyclonal antibody therapeutic to address complications from smallpox vaccination. It also provides NARCAN and KLOXXADO nasal sprays for the emergency treatment of known or suspected opioid overdose. In addition, the company offers contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, analytical development, and suite reservation services. Emergent BioSolutions Inc. was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.
đ° Latest News
Emergent BioSolutions Inc. (EBS) Gains Attention as ACAM2000 Receives Broader Public Health Authorization
Insider Monkey âĸ 2026-05-20T20:43:44Z
Emergent BioSolutions Shares Turnaround Update at 2026 Annual Meeting; All Proposals Approved
MarketBeat âĸ 2026-05-02T14:29:55Z
Emergent BioSolutions Inc. Q1 2026 Earnings Call Summary
Moby âĸ 2026-05-01T12:30:00Z
Emergent Biosolutions Q1 Earnings Call Highlights
MarketBeat âĸ 2026-05-01T11:18:45Z
Emergent BioSolutions Inc (EBS) Q1 2026 Earnings Call Highlights: Strong Revenue and Strategic ...
GuruFocus.com âĸ 2026-05-01T07:19:55ZHow The Emerging Narrative On Emergent BioSolutions (EBS) Is Shifting After The Earnings Miss
Simply Wall St. âĸ 2026-04-23T10:05:54Z
McKinsey Will Add $125 Million to Purdue's $7 Billion Bankruptcy Settlement
Moby âĸ 2026-04-09T18:34:01Z
A Look At Erste Group Bankâs (WBAG:EBS) Valuation Following Recent Share Price Softness
Simply Wall St. âĸ 2026-04-03T11:12:42Z
How The Reset Price Target Is Shaping The Emergent BioSolutions (EBS) Investment Story
Simply Wall St. âĸ 2026-03-25T23:07:37Z
How The Investment Narrative For Emergent BioSolutions (EBS) Is Shifting After The $12 Target Reset
Simply Wall St. âĸ 2026-03-10T19:16:33Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $295,500,000 | $637,600,000 | $645,900,000 | $609,700,000 |
| Cost Of Revenue | $326,200,000 | $681,300,000 | $705,400,000 | $693,100,000 |
| Total Revenue | $705,200,000 | $1,013,600,000 | $1,023,000,000 | $1,076,100,000 |
| Operating Revenue | $705,200,000 | $1,013,600,000 | $1,023,000,000 | $1,076,100,000 |
| Expenses | ||||
| Interest Expense | $59,300,000 | $71,000,000 | $87,900,000 | $37,300,000 |
| Total Expenses | $592,900,000 | $1,095,100,000 | $1,224,500,000 | $1,239,400,000 |
| Other Income Expense | $29,800,000 | $9,600,000 | $-441,800,000 | $-18,400,000 |
| Other Non Operating Income Expenses | $54,200,000 | $11,900,000 | $6,400,000 | $-11,700,000 |
| Net Non Operating Interest Income Expense | $-59,300,000 | $-71,000,000 | $-87,900,000 | $-37,300,000 |
| Interest Expense Non Operating | $59,300,000 | $71,000,000 | $87,900,000 | $37,300,000 |
| Operating Expense | $266,700,000 | $413,800,000 | $519,100,000 | $546,300,000 |
| Other Operating Expenses | $-37,700,000 | $-30,000,000 | $-26,300,000 | $-41,400,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $52,600,000 | $-190,600,000 | $-760,500,000 | $-211,600,000 |
| Net Interest Income | $-59,300,000 | $-71,000,000 | $-87,900,000 | $-37,300,000 |
| Normalized Income | $68,094,000 | $-188,783,000 | $-406,422,000 | $-205,101,000 |
| Net Income From Continuing And Discontinued Operation | $52,600,000 | $-190,600,000 | $-760,500,000 | $-211,600,000 |
| Total Operating Income As Reported | $100,100,000 | $-108,700,000 | $-726,400,000 | $-170,000,000 |
| Net Income Common Stockholders | $52,600,000 | $-190,600,000 | $-760,500,000 | $-211,600,000 |
| Net Income | $52,600,000 | $-190,600,000 | $-760,500,000 | $-211,600,000 |
| Net Income Including Noncontrolling Interests | $52,600,000 | $-190,600,000 | $-760,500,000 | $-211,600,000 |
| Net Income Continuous Operations | $52,600,000 | $-190,600,000 | $-760,500,000 | $-211,600,000 |
| Pretax Income | $82,800,000 | $-142,900,000 | $-731,200,000 | $-219,000,000 |
| Special Income Charges | $-24,400,000 | $-2,300,000 | $-448,200,000 | $-6,700,000 |
| Operating Income | $112,300,000 | $-81,500,000 | $-201,500,000 | $-163,300,000 |
| Depreciation Amortization Depletion Income Statement | $65,100,000 | $65,100,000 | $65,600,000 | $59,900,000 |
| Depreciation And Amortization In Income Statement | $65,100,000 | $65,100,000 | $65,600,000 | $59,900,000 |
| Amortization Of Intangibles Income Statement | $65,100,000 | $65,100,000 | $65,600,000 | $59,900,000 |
| Gross Profit | $379,000,000 | $332,300,000 | $317,600,000 | $383,000,000 |
| Per Share | ||||
| Diluted EPS | $0.93 | $-3.60 | $-14.85 | $-4.47 |
| Basic EPS | $0.98 | $-3.60 | $-14.85 | $-4.47 |
| Other | ||||
| Tax Effect Of Unusual Items | $-8,906,000 | $-483,000 | $-94,122,000 | $-201,000 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $262,300,000 | $39,200,000 | $-70,000,000 | $-31,700,000 |
| Total Unusual Items | $-24,400,000 | $-2,300,000 | $-448,200,000 | $-6,700,000 |
| Total Unusual Items Excluding Goodwill | $-24,400,000 | $-2,300,000 | $-448,200,000 | $-6,700,000 |
| Reconciled Depreciation | $95,800,000 | $108,800,000 | $125,100,000 | $143,300,000 |
| EBITDA (Bullshit earnings) | $237,900,000 | $36,900,000 | $-518,200,000 | $-38,400,000 |
| EBIT | $142,100,000 | $-71,900,000 | $-643,300,000 | $-181,700,000 |
| Diluted Average Shares | $56,700,000 | $53,000,000 | $51,200,000 | $50,100,000 |
| Basic Average Shares | $53,500,000 | $53,000,000 | $51,200,000 | $50,100,000 |
| Diluted NI Availto Com Stockholders | $52,600,000 | $-190,600,000 | $-760,500,000 | $-211,600,000 |
| Tax Provision | $30,200,000 | $47,700,000 | $29,300,000 | $-7,400,000 |
| Gain On Sale Of Business | $0 | $24,300,000 | $74,200,000 | $0 |
| Other Special Charges | $12,200,000 | $-600,000 | $-2,500,000 | - |
| Impairment Of Capital Assets | $12,200,000 | $27,200,000 | $524,900,000 | $6,700,000 |
| Amortization | $65,100,000 | $65,100,000 | $65,600,000 | $59,900,000 |
| Research And Development | $53,200,000 | $70,700,000 | $111,400,000 | $188,300,000 |
| Selling General And Administration | $186,100,000 | $308,000,000 | $368,400,000 | $339,500,000 |
Fetched: 2026-06-20
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $86,100,000 | $-18,700,000 | $82,700,000 | $440,700,000 |
| Total Assets | $1,318,600,000 | $1,389,700,000 | $1,823,200,000 | $3,166,300,000 |
| Total Non Current Assets | $656,100,000 | $791,000,000 | $1,143,700,000 | $1,955,900,000 |
| Other Non Current Assets | $14,200,000 | $18,900,000 | $194,300,000 | $191,300,000 |
| Goodwill And Other Intangible Assets | $436,500,000 | $501,500,000 | $566,600,000 | $947,000,000 |
| Other Intangible Assets | $436,500,000 | $501,500,000 | $566,600,000 | $728,800,000 |
| Current Assets | $662,500,000 | $598,700,000 | $679,500,000 | $1,210,400,000 |
| Other Current Assets | $25,800,000 | $26,900,000 | $47,900,000 | $57,900,000 |
| Restricted Cash | $3,700,000 | $6,100,000 | $0 | $0 |
| Inventory | $343,400,000 | $311,700,000 | $328,900,000 | $350,700,000 |
| Receivables | $84,200,000 | $154,500,000 | $191,000,000 | $159,200,000 |
| Receivables Adjustments Allowances | $-800,000 | $-500,000 | $-2,200,000 | $-700,000 |
| Other Receivables | $18,200,000 | $19,600,000 | $51,400,000 | $57,200,000 |
| Accounts Receivable | $66,800,000 | $135,400,000 | $141,800,000 | $102,700,000 |
| Gross Accounts Receivable | $66,800,000 | $135,400,000 | $141,800,000 | $102,700,000 |
| Cash Cash Equivalents And Short Term Investments | $205,400,000 | $99,500,000 | $111,700,000 | $642,600,000 |
| Cash And Cash Equivalents | $205,400,000 | $99,500,000 | $111,700,000 | $642,600,000 |
| Allowance For Doubtful Accounts Receivable | - | - | - | $-700,000 |
| Prepaid Assets | - | - | - | - |
| Debt | ||||
| Net Debt | $366,700,000 | $564,200,000 | $748,500,000 | $763,200,000 |
| Total Debt | $572,100,000 | $663,700,000 | $860,200,000 | $1,405,800,000 |
| Long Term Debt And Capital Lease Obligation | $572,100,000 | $663,700,000 | $446,500,000 | $448,500,000 |
| Long Term Debt | $572,100,000 | $663,700,000 | $446,500,000 | $448,500,000 |
| Current Debt And Capital Lease Obligation | - | - | $413,700,000 | $957,300,000 |
| Current Debt | - | - | $413,700,000 | $957,300,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $796,000,000 | $906,900,000 | $1,173,900,000 | $1,778,600,000 |
| Total Non Current Liabilities Net Minority Interest | $663,800,000 | $744,500,000 | $522,600,000 | $549,700,000 |
| Other Non Current Liabilities | $53,900,000 | $39,100,000 | $28,900,000 | $41,500,000 |
| Non Current Deferred Liabilities | $37,800,000 | $41,700,000 | $47,200,000 | $59,700,000 |
| Non Current Deferred Taxes Liabilities | $37,800,000 | $41,700,000 | $47,200,000 | $59,700,000 |
| Current Liabilities | $132,200,000 | $162,400,000 | $651,300,000 | $1,228,900,000 |
| Other Current Liabilities | $15,800,000 | $21,900,000 | $32,700,000 | $45,900,000 |
| Payables And Accrued Expenses | $74,600,000 | $84,400,000 | $130,800,000 | $138,400,000 |
| Payables | $62,400,000 | $66,700,000 | $112,200,000 | $103,500,000 |
| Total Tax Payable | $6,800,000 | $5,800,000 | - | - |
| Accounts Payable | $55,600,000 | $60,900,000 | $112,200,000 | $103,500,000 |
| Equity | ||||
| Common Stock Equity | $522,600,000 | $482,800,000 | $649,300,000 | $1,387,700,000 |
| Total Equity Gross Minority Interest | $522,600,000 | $482,800,000 | $649,300,000 | $1,387,700,000 |
| Stockholders Equity | $522,600,000 | $482,800,000 | $649,300,000 | $1,387,700,000 |
| Gains Losses Not Affecting Retained Earnings | $-7,500,000 | $-5,200,000 | $-5,700,000 | $3,100,000 |
| Other Equity Adjustments | $-7,500,000 | $-5,200,000 | $-5,700,000 | $3,100,000 |
| Retained Earnings | $-159,800,000 | $-212,400,000 | $-21,800,000 | $738,700,000 |
| Other | ||||
| Treasury Shares Number | $8,700,000 | $5,600,000 | $5,600,000 | $5,600,000 |
| Ordinary Shares Number | $52,100,000 | $54,329,542 | $52,200,000 | $50,100,000 |
| Share Issued | $60,800,000 | $59,929,542 | $57,800,000 | $55,700,000 |
| Tangible Book Value | $86,100,000 | $-18,700,000 | $82,700,000 | $440,700,000 |
| Invested Capital | $1,094,700,000 | $1,146,500,000 | $1,509,500,000 | $2,793,500,000 |
| Working Capital | $530,300,000 | $436,300,000 | $28,200,000 | $-18,500,000 |
| Total Capitalization | $1,094,700,000 | $1,146,500,000 | $1,095,800,000 | $1,836,200,000 |
| Treasury Stock | $252,600,000 | $227,700,000 | $227,700,000 | $227,700,000 |
| Additional Paid In Capital | $942,400,000 | $928,000,000 | $904,400,000 | $873,500,000 |
| Capital Stock | $100,000 | $100,000 | $100,000 | $100,000 |
| Common Stock | $100,000 | $100,000 | $100,000 | $100,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Pensionand Other Post Retirement Benefit Plans Current | $41,800,000 | $56,100,000 | $74,100,000 | $87,300,000 |
| Current Accrued Expenses | $12,200,000 | $17,700,000 | $18,600,000 | $34,900,000 |
| Net PPE | $205,400,000 | $270,600,000 | $382,800,000 | $817,600,000 |
| Accumulated Depreciation | $-304,100,000 | $-397,100,000 | $-411,400,000 | $-383,800,000 |
| Gross PPE | $509,500,000 | $667,700,000 | $794,200,000 | $1,201,400,000 |
| Construction In Progress | $6,600,000 | $10,300,000 | $36,700,000 | $185,500,000 |
| Machinery Furniture Equipment | $321,700,000 | $435,500,000 | $497,600,000 | $633,100,000 |
| Buildings And Improvements | $160,500,000 | $196,100,000 | $229,900,000 | $327,900,000 |
| Land And Improvements | $20,700,000 | $25,800,000 | $30,000,000 | $54,900,000 |
| Properties | $0 | $0 | $0 | $0 |
| Finished Goods | $113,800,000 | $129,500,000 | $86,900,000 | $92,200,000 |
| Work In Process | $109,000,000 | $86,300,000 | $113,300,000 | $116,200,000 |
| Raw Materials | $120,600,000 | $95,900,000 | $128,700,000 | $142,300,000 |
| Goodwill | - | - | $0 | $218,200,000 |
| Non Current Deferred Revenue | - | - | - | - |
Fetched: 2026-06-20
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $156,800,000 | $35,800,000 | $-257,900,000 | $-149,900,000 |
| Operating Activities | ||||
| Operating Cash Flow | $170,600,000 | $58,700,000 | $-206,300,000 | $-34,100,000 |
| Cash Flow From Continuing Operating Activities | $170,600,000 | $58,700,000 | $-206,300,000 | $-34,100,000 |
| Operating Gains Losses | $10,000,000 | $-2,400,000 | $-53,100,000 | $3,600,000 |
| Investing Activities | ||||
| Capital Expenditure | $-13,800,000 | $-22,900,000 | $-51,600,000 | $-115,800,000 |
| Investing Cash Flow | $69,400,000 | $125,200,000 | $212,300,000 | $-381,300,000 |
| Cash Flow From Continuing Investing Activities | $69,400,000 | $125,200,000 | $212,300,000 | $-381,300,000 |
| Net Other Investing Changes | $45,000,000 | $30,000,000 | $-6,300,000 | $-265,500,000 |
| Financing Activities | ||||
| Repurchase Of Capital Stock | $-24,900,000 | $0 | $0 | $-82,100,000 |
| Issuance Of Capital Stock | $0 | $9,300,000 | $8,400,000 | $0 |
| Financing Cash Flow | $-136,600,000 | $-190,000,000 | $-535,700,000 | $481,200,000 |
| Cash Flow From Continuing Financing Activities | $-136,600,000 | $-190,000,000 | $-535,700,000 | $481,200,000 |
| Net Other Financing Charges | $-5,200,000 | $-15,800,000 | $-2,500,000 | $-5,900,000 |
| Net Common Stock Issuance | $-24,900,000 | $9,300,000 | $8,400,000 | $-82,100,000 |
| Common Stock Issuance | $0 | $9,300,000 | $8,400,000 | $0 |
| Other | ||||
| Repayment Of Debt | $-108,700,000 | $-482,400,000 | $-563,400,000 | $-33,800,000 |
| Issuance Of Debt | $0 | $284,000,000 | $20,000,000 | $598,000,000 |
| Interest Paid Supplemental Data | $49,700,000 | $64,000,000 | $68,300,000 | $33,000,000 |
| Income Tax Paid Supplemental Data | $40,000,000 | $26,500,000 | $52,800,000 | $6,200,000 |
| End Cash Position | $209,100,000 | $105,600,000 | $111,700,000 | $642,600,000 |
| Beginning Cash Position | $105,600,000 | $111,700,000 | $642,600,000 | $576,300,000 |
| Effect Of Exchange Rate Changes | $100,000 | $0 | $-1,200,000 | $500,000 |
| Changes In Cash | $103,400,000 | $-6,100,000 | $-529,700,000 | $65,800,000 |
| Proceeds From Stock Option Exercised | $2,200,000 | $14,900,000 | $1,800,000 | $5,000,000 |
| Common Stock Payments | $-24,900,000 | $0 | $0 | $-82,100,000 |
| Net Issuance Payments Of Debt | $-108,700,000 | $-198,400,000 | $-543,400,000 | $564,200,000 |
| Net Long Term Debt Issuance | $-108,700,000 | $-198,400,000 | $-543,400,000 | $564,200,000 |
| Long Term Debt Payments | $-108,700,000 | $-482,400,000 | $-563,400,000 | $-33,800,000 |
| Long Term Debt Issuance | $0 | $284,000,000 | $20,000,000 | $598,000,000 |
| Net Business Purchase And Sale | $0 | $110,200,000 | $270,200,000 | $0 |
| Sale Of Business | $0 | $110,200,000 | $270,200,000 | $0 |
| Net PPE Purchase And Sale | $24,400,000 | $-15,000,000 | $-51,600,000 | $-115,800,000 |
| Sale Of PPE | $38,200,000 | $7,900,000 | $0 | $0 |
| Purchase Of PPE | $-13,800,000 | $-22,900,000 | $-51,600,000 | $-115,800,000 |
| Change In Working Capital | $-22,400,000 | $88,700,000 | $-70,300,000 | $-2,100,000 |
| Change In Other Working Capital | $6,600,000 | $6,600,000 | $-5,500,000 | $38,300,000 |
| Change In Payables And Accrued Expense | $-35,900,000 | $-38,900,000 | $-55,500,000 | $-81,500,000 |
| Change In Accrued Expense | $-27,500,000 | $-5,900,000 | $-66,100,000 | $-67,500,000 |
| Change In Payable | $-8,400,000 | $-33,000,000 | $10,600,000 | $-14,000,000 |
| Change In Account Payable | $-8,400,000 | $-33,000,000 | $10,600,000 | $-14,000,000 |
| Change In Prepaid Assets | $11,700,000 | $169,900,000 | $11,700,000 | $-19,900,000 |
| Change In Inventory | $-30,300,000 | $-24,500,000 | $600,000 | $-57,100,000 |
| Change In Receivables | $25,500,000 | $-24,400,000 | $-21,600,000 | $118,100,000 |
| Changes In Account Receivables | $25,500,000 | $-24,400,000 | $-21,600,000 | $118,100,000 |
| Other Non Cash Items | $10,200,000 | $14,500,000 | $13,400,000 | $9,500,000 |
| Stock Based Compensation | $16,200,000 | $18,000,000 | $23,100,000 | $45,100,000 |
| Asset Impairment Charge | $12,200,000 | $27,200,000 | $524,900,000 | $6,700,000 |
| Deferred Tax | $-4,000,000 | $-5,500,000 | $-8,900,000 | $-28,600,000 |
| Deferred Income Tax | $-4,000,000 | $-5,500,000 | $-8,900,000 | $-28,600,000 |
| Depreciation Amortization Depletion | $95,800,000 | $108,800,000 | $125,100,000 | $143,300,000 |
| Depreciation And Amortization | $95,800,000 | $108,800,000 | $125,100,000 | $143,300,000 |
| Amortization Cash Flow | $65,100,000 | $65,100,000 | $65,600,000 | $59,900,000 |
| Amortization Of Intangibles | $65,100,000 | $65,100,000 | $65,600,000 | $59,900,000 |
| Depreciation | $30,700,000 | $43,700,000 | $59,500,000 | $83,400,000 |
| Gain Loss On Investment Securities | $5,500,000 | $1,100,000 | - | - |
| Gain Loss On Sale Of Business | $0 | $-32,200,000 | $-74,200,000 | $0 |
| Net Income From Continuing Operations | $52,600,000 | $-190,600,000 | $-760,500,000 | $-211,600,000 |
| Net Short Term Debt Issuance | - | - | - | $598,000,000 |
| Short Term Debt Payments | - | - | - | $0 |
| Short Term Debt Issuance | - | - | - | $598,000,000 |
| Net Intangibles Purchase And Sale | - | - | - | $-21,800,000 |
| Purchase Of Intangibles | - | - | - | $-21,800,000 |
Fetched: 2026-06-20